Lillian Werner
Overview
Explore the profile of Lillian Werner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
2660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parry E, Lemvigh C, Deng S, Dangle N, Ruthen N, Knisbacher B, et al.
Cancer Cell
. 2023 Sep;
41(10):1803-1816.e8.
PMID: 37738974
Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response,...
2.
Miller P, Qiao D, Rojas-Quintero J, Honigberg M, Sperling A, Gibson C, et al.
Blood
. 2021 Dec;
139(3):357-368.
PMID: 34855941
Chronic obstructive pulmonary disease (COPD) is associated with age and smoking, but other determinants of the disease are incompletely understood. Clonal hematopoiesis of indeterminate potential (CHIP) is a common, age-related...
3.
Mantia C, Werner L, Stwalley B, Ritchings C, Tarhini A, Atkins M, et al.
Melanoma Res
. 2021 Dec;
32(1):35-44.
PMID: 34855329
Patients with advanced melanoma treated with immune checkpoint inhibitors can experience ongoing disease control after treatment discontinuation without subsequent systemic anticancer therapy. We previously defined a novel outcome, treatment-free survival...
4.
Regan M, Mantia C, Werner L, Tarhini A, Larkin J, Hodi F, et al.
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34799400
Background: Treatment-free survival (TFS) characterizes disease control after discontinuation of immune checkpoint inhibitors (ICIs) until subsequent therapy or death. We previously evaluated TFS in a pooled analysis of the CheckMate...
5.
Regan M, Jegede O, Mantia C, Powles T, Werner L, Motzer R, et al.
Clin Cancer Res
. 2021 Nov;
27(24):6687-6695.
PMID: 34759043
Purpose: Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity may persist. We describe treatment-free survival (TFS), with and without toxicity....
6.
Knudsen T, Skov V, Stevenson K, Werner L, Duke W, Laurore C, et al.
Blood Adv
. 2021 Sep;
6(7):2107-2119.
PMID: 34507355
Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing...
7.
McKay R, Kwak L, Crowdis J, Sperger J, Zhao S, Xie W, et al.
Clin Cancer Res
. 2021 Apr;
27(13):3610-3619.
PMID: 33849963
Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC). However, nearly all patients develop resistance. We designed a...
8.
Bowden M, Nadal R, Zhou C, Werner L, Barletta J, Juanpere N, et al.
Sci Rep
. 2020 Nov;
10(1):20135.
PMID: 33208770
No consensus currently exist on the optimal treatment of patients with high-risk nonmuscle invasive (HGT1) micropapillary variant of bladder cancer (MPBC). Transcripsome analysis may allow stratification of MPBC-HGT1 enabling prediction...
9.
Vicier C, Ravi P, Kwak L, Werner L, Huang Y, Evan C, et al.
Prostate
. 2020 Sep;
81(1):50-57.
PMID: 32986884
Background: Characterization of markers of both immune suppression and activation may provide more prognostic information than assessment of single markers in localized prostate cancer. We therefore sought to determine the...
10.
Wei X, Werner L, Teo M, Rosenberg J, Koshkin V, Grivas P, et al.
J Urol
. 2020 Sep;
205(2):414-419.
PMID: 32935617
Purpose: Current first line treatment options in patients with metastatic urothelial carcinoma unfit to receive cisplatin containing chemotherapy include PD-1/L1 inhibitors and carboplatin containing chemotherapy. However, the optimal sequencing of...